Osteopontin-C mediates the upregulation of androgen responsive genes in LNCaP cells through PI3K/Akt and androgen receptor signaling

Oncology Letters

Volumn 9, Issue 4, 2015, Pages 1845-1850

  Tilli, Tatiana Martins ^a   Ferreira, Luciana Bueno ^b   Gimba, Etel Rodrigues Pereira ^a,c  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b UNIVERSITY OF PORTO   (Portugal)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Androgen receptor signaling; OPNc; Osteopontin; Splice variant

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; OSTEOPONTIN; OSTEOPONTIN C; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMID VECTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL CULTURE; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION;

EID: 84923171566     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.2939     Document Type: Article

References (39)

1. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW and Fedarko NS: Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat Rev Cancer 8: 212-226, 2008.
2. Zhang Y, Forootan SS, Kamalian L, et al: Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression. Int J Oncol 38: 1083-1091, 2011.
3. Zheng J, Hou ZB and Jiao NL: Effects of osteopontin downregulation on the growth of prostate cancer PC-3 cells. Mol Med Rep 4: 1225-1231, 2011.
4. He B, Mirza M and Weber GF: An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25: 2192-2202, 2006.
5. Gimba ER and Tilli TM: Human osteopontin splicing isoforms: Known roles, potential clinical applications and activated signaling pathways. Cancer Lett 331: 11-17, 2013.
6. Puzone R, Paleari L, Montefiore F, et al: Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy. Int J Biol Markers 25: 200-206, 2010.
7. Thoms JW, Dal Pra A, Anborgh PH, et al: Plasma osteopontin as a biomarker of prostate cancer aggression: Relationship to risk category and treatment response. Br J Cancer 107: 840-846, 2012.
8. Weber GF, Lett GS and Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 103: 861-869, 2010.
9. Weber GF, Lett GS and Haubein NC: Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep 25: 433-441, 2011.
10. Tilli TM, Mello KD, Ferreira LB, et al: Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 72: 1688-1699, 2012.
11. Tilli TM, Thuler LC, Matos AR, et al: Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp Mol Pathol 92: 13-19, 2012.
12. Martinez HD, Hsiao JJ, Jasavala RJ, Hinkson IV, Eng JK and Wright ME: Androgen-sensitive microsomal signaling networks coupled to the proliferation and differentiation of human prostate cancer cells. Genes Cancer 2: 956-978, 2011.
13. Takayama K, Tsutsumi S, Katayama S, et al: Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30: 619-630, 2011.
14. Liu X, Choi RY, Jawad SM and Arnold JT: Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells. Prostate 71: 766-777, 2011.
15. Bitting RL and Armstrong AJ: Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 20: R83-R99, 2013.
16. Terracciano D, Mazzarella C, Di Carlo A, et al: Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. Oncol Rep 24: 213-217, 2010.
17. Zhu H and Garcia JA: Targeting the adrenal gland in castration-resistant prostate cancer: A case for orteronel, a selective CYP-17 17,20-lyase inhibitor. Curr Oncol Rep 15: 105-112, 2013.
18. Elo TD, Valve EM, Seppänen JA, et al: Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice. Neoplasia 12: 915-927, 2010.
19. Angelucci A, Festuccia C, Gravina GL, et al: Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 59: 157-166, 2004.
20. Tilli TM, Bellahcène A, Castronovo V and Gimba ER: Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines. BMC Cancer 14: 433, 2014.
21. Ngan S, Stronach EA, Photiou A, Waxman J, Ali S and Buluwela L: Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 28: 2051-2063, 2009.
22. Mattila MM and Härkönen PL: Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev 18: 257-266, 2007.
23. Ferreira LB, Palumbo A, de Mello KD, et al: PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer 12: 507, 2012.
24. Flores O, Wang Z, Knudsen KE and Burnstein KL: Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 151: 896-908, 2010.
25. Rae JM, Johnson MD, Cordero KE, et al: GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate 66: 886-894, 2006.
26. Lilja H: Biology of prostate-specific antigen. Urology 62 (Suppl 1): 27-33, 2003.
27. Chen YW, Lee MS, Lucht A, et al: TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. Am J Pathol 176: 2986-2996, 2010.
28. Tomlins SA, Laxman B, Varambally S, et al: Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188, 2008.
29. Li H, Xu LL, Masuda K, et al: A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem 283: 28988-28995, 2008.
30. Richter E, Masuda K, Cook C, et al: A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer. Epigenetics 2: 100-109, 2007.
31. Mattsson JM, Laakkonen P, Stenman UH and Koistinen H: Antiangiogenic properties of prostate-specific antigen (PSA). Scand J Clin Lab Invest 69: 447-451, 2009.
32. Guo Y, Pili R and Passaniti A: Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix. Prostate 24: 1-10, 1994.
33. Sica G, Iacopino F, Settesoldi D and Zelano G: Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells. Eur Urol 35 (Suppl 1): 2-8, 1999.
34. Valdez CD, Davis JN, Odeh HM, et al: Repression of androgen receptor transcription through the E2F1/DNMT1 axis. PloS One 6: 25187, 2011.
35. Shiota M, Yokomizo A and Naito S: Increased androgen receptor transcription: A cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 47: R25-R41, 2011.
36. Hou X, Li Z, Huang W, et al: Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate 73: 1352-1363, 2013.
37. Baena E, Shao Z, Linn DE, et al: ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 27: 683-698, 2013.
38. Patki M, Chari V, Sivakumaran S, Gonit M, Trumbly R and Ratnam M: The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells. J Biol Chem 288: 11047-11065, 2013.
39. Chun JY, Nadiminty N, Dutt S, et al: Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 15: 4815-4822, 2009.